| 2017 | Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study | EUROPEAN JOURNAL OF CANCER |
| 2017 | Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score | JAMA ONCOLOGY |
| 2014 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | LANCET |
| 2014 | Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. | LANCET |
| 2022 | Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16) | GASTRIC CANCER |
| 2021 | Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2018 | Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. | JOURNAL OF GLOBAL ONCOLOGY |
| 2015 | Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial | LANCET ONCOLOGY |
| 2017 | RanBPM: a potential therapeutic target for modulating diverse physiological disorders | DRUG DISCOVERY TODAY |
| 2013 | Random and site-specific mutagenesis of the Helicobacter pylori ferric uptake regulator provides insight into Fur structure–function relationships | MOLECULAR MICROBIOLOGY |
| 2009 | Random forests 기법을 이용한 백내장 예측모형 : 일개 대학병원 건강검진 수검자료에서
| Korean Journal of Applied Statistics (응용통계연구) |
| 2013 | Random urine protein/creatinine ratio readily predicts proteinuria in preeclampsia
| Obstetrics & Gynecology Science |
| 2023 | Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis
| ALIMENTARY PHARMACOLOGY & THERAPEUTICS |
| 2021 | Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease
| ALIMENTARY PHARMACOLOGY & THERAPEUTICS |
| 2014 | Randomised comparison of strut coverage between Nobori biolimus-eluting and sirolimus-eluting stents: an optical coherence tomography analysis. | EUROINTERVENTION |
| 2017 | Randomised controlled clinical trial of augmentation of the alveolar ridge using recombinant human bone morphogenetic protein 2 with hydroxyapatite and bovine-derived xenografts: comparison of changes in volume | BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY |
| 2023 | Randomised controlled trial of a behavioural intervention to reduce exposure to PM2.5 in patients with COPD
| ENVIRONMENT INTERNATIONAL |
| 2021 | Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
| BRITISH JOURNAL OF CANCER |
| 2019 | Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis
| ALIMENTARY PHARMACOLOGY & THERAPEUTICS |
| 2019 | Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer | EUROPEAN JOURNAL OF CANCER |
